MedTrace Logo

Probing the Cannabinoid System in Individuals With a Family History of Psychosis

NCT02102113 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2025-06-10

No results posted yet for this study

Summary

The overall purpose of this study is to determine whether a family history of psychosis is associated with an altered cannabinoid system. This will be tested by studying individuals with and without a family history of psychosis and comparing their responses to delta 9-tetrahydrocannabinol (THC), a probe of the cannabinoid system. We hypothesize, that compared to controls with no family history of psychoses, individuals with a family history of psychoses will have an altered response to THC.

Conditions

Interventions

DRUG

Placebo

placebo

DRUG

Very Low Dose THC

Subjects will receive 0.010mg/kg.

DRUG

Low Dose THC

Subjects will receive 0.018 mg/kg over 20 minutes.

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Mohini Ranganathan, MD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2026-06-30
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02102113 on ClinicalTrials.gov